Home » Stocks » CFMS

Conformis, Inc. (CFMS)

Stock Price: $1.22 USD 0.18 (17.31%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.18 -0.04 (-3.28%) Jan 15, 7:58 PM
Market Cap 104.85M
Revenue (ttm) 71.95M
Net Income (ttm) -23.10M
Shares Out 71.22M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.22
Previous Close $1.04
Change ($) 0.18
Change (%) 17.31%
Day's Open 1.07
Day's Range 1.05 - 1.37
Day's Volume 8,175,574
52-Week Range 0.56 - 1.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 2 weeks ago

BILLERICA, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leader in patient-specific knee and hip instrumentation and implants, announced today that Mark Augusti, C...

GlobeNewsWire - 4 weeks ago

Cordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis' state-of-the-art, personalized pre-operative plans and patient-specific instruments. Cordera™ Match Hip System c...

GlobeNewsWire - 1 month ago

BILLERICA, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Off...

GlobeNewsWire - 2 months ago

BILLERICA, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.

Seeking Alpha - 2 months ago

Conformis's (CFMS) CEO Mark Augusti on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

ConforMIS (CFMS) delivered earnings and revenue surprises of 25.00% and 0.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

BILLERICA, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020.

Benzinga - 2 months ago

Conformis (NASDAQ: CFMS) releases its next round of earnings this Wednesday, November 04. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.

GlobeNewsWire - 2 months ago

BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Off...

Zacks Investment Research - 2 months ago

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

Earnings Call to be Hosted on November 4, 2020 Earnings Call to be Hosted on November 4, 2020

GlobeNewsWire - 3 months ago

Cordera™ Hip System with optional patient-specific instrumentation and personalized surgical plan joins the 3D Conformis Hip System as the latest hip technology from Conformis Cordera™ Hip Sys...

GlobeNewsWire - 3 months ago

BILLERICA, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investo...

GlobeNewsWire - 3 months ago

BILLERICA, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held Septembe...

GlobeNewsWire - 4 months ago

BILLERICA, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22nd Annual Global Investment Conference, to be held ...

GlobeNewsWire - 4 months ago

BILLERICA, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s exec...

GlobeNewsWire - 4 months ago

BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Devel...

GlobeNewsWire - 5 months ago

BILLERICA, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Farzin Khaghani as its new VP, US Marketing.

GlobeNewsWire - 5 months ago

Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posteri...

Zacks Investment Research - 5 months ago

ConforMIS (CFMS) delivered earnings and revenue surprises of 76.92% and 32.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 5 months ago

Conformis' (CFMS) CEO Mark Augusti on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

BILLERICA, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the second quarter ended June 30, 2020.

GlobeNewsWire - 5 months ago

BILLERICA, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The eve...

Zacks Investment Research - 5 months ago

ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

Earnings Call to be Hosted on August 5, 2020

Zacks Investment Research - 6 months ago

Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.

GlobeNewsWire - 6 months ago

iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology...

GlobeNewsWire - 7 months ago

Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants Conformis and Zimmer Biomet settled disp...

GlobeNewsWire - 7 months ago

Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to...

Seeking Alpha - 8 months ago

Conformis (CFMS) CEO Mark Augusti on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

ConforMIS (CFMS) delivered earnings and revenue surprises of -55.56% and -13.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

BILLERICA, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West...

GlobeNewsWire - 9 months ago

Withdraws Previous 2020 Growth Outlook

Zacks Investment Research - 10 months ago

Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

Other stocks mentioned: KL, LONE, NOVN, UEC
Seeking Alpha - 10 months ago

Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

ConforMIS (CFMS) delivered earnings and revenue surprises of 20.00% and -0.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty

GlobeNewsWire - 11 months ago

Also Announces Gary Maingot as SVP, Operations; New Executive Leadership Team Members Contribute Deep Functional Expertise and Technical Knowledge; Inducement Grants Reported Also Announces Ga...

Seeking Alpha - 11 months ago

Conformis: An Update On The New Total Hip Replacement System

GlobeNewsWire - 11 months ago

Conformis’ Patient-Specific Knee Implant Technology Is Complemented by New 3D-designed Hip System Launched in November 2019 Conformis’ Patient-Specific Knee Implant Technology Is Complemented ...

GlobeNewsWire - 1 year ago

BILLERICA, Mass. and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology p...

Seeking Alpha - 1 year ago

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Other stocks mentioned: ATNX, BSX, DARE
Zacks Investment Research - 1 year ago

Inside the best performing stocks of the Russell 2000 ETF.

Other stocks mentioned: ACHN, APPS, EVER, IWM, KOD
Seeking Alpha - 1 year ago

Conformis' (CFMS) CEO Mark Augusti on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ConforMIS (CFMS) delivered earnings and revenue surprises of -18.18% and -2.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BILLERICA, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop...

24/7 Wall Street - 1 year ago

Conformis Inc. (NASDAQ: CFMS) shares shot up on Tuesday after the firm announced that it has entered into definitive agreements to sell and license to Stryker Corp.

About CFMS

Conformis, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized... [Read more...]

Industry
Medical Devices
IPO Date
Jul 1, 2015
CEO
Mark A. Augusti
Employees
262
Stock Exchange
NASDAQ
Ticker Symbol
CFMS
Full Company Profile

Financial Performance

In 2019, Conformis's revenue was $77.43 million, a decrease of -13.77% compared to the previous year's $89.79 million. Losses were -$28.48 million, -34.33% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Conformis stock is "Buy." The 12-month stock price forecast is 2.33, which is an increase of 90.98% from the latest price.

Price Target
$2.33
(90.98% upside)
Analyst Consensus: Buy